AOP Orphan Pharmaceuticals AG
A-1160 Wien
Wilhelminenstraße
Vienna
91/ II f / B4
Tel: 43-1-5037244-22
Fax: 43-1-5037244-61
Website: http://www.aoporphan.at/index.php?id=22&L=2
Email: office@aoporphan.at
28 articles about AOP Orphan Pharmaceuticals AG
-
Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera to Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting
12/7/2023
AOP Orphan Pharmaceuticals GmbH announced the results of an analysis assessing the impact of an individually optimized dosing regimen of ropeginterferon alfa-2b on treatment response in patients with low-risk polycythaemia vera 1 These new data show that some low-risk PV patients require and can tolerate high ropeginterferon alfa-2b doses, and that the optimal dose varies substantially between patients.
-
Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera Published in Medical Journal Leukemia
9/19/2023
AOP Orphan Pharmaceuticals GmbH announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera in the prestigious journal Leukemia.
-
AOP Health Starts Research for Leukemia Treatment
8/1/2022
The AOP Health Group is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria.
-
BESREMi® (Ropeginterferon alfa-2b) approved by the US FDA
11/15/2021
The US Food & Drug Administration (FDA) approved BESREMi® (active pharmaceutical ingredient Ropeginterferon alfa-2b), confirming the efficacy and safety for treatment of Polycythaemia Vera, a rare blood cancer disease.
-
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
8/9/2021
Eagle Pharmaceuticals, Inc. announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH, a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States.
-
BioSpace Global Roundup, Oct. 15
10/15/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi™ (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
12/17/2018
PharmaEssentia today announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Besremi, intended for the treatment of polycythaemia vera without symptomatic splenomegaly. The applicant for Besremi is AOP Orphan Pharmaceuticals AG (AOP Orphan).
-
AOP Orphan Announces Progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b
6/11/2018
AOP Orphan´s submission for marketing authorization of Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) in the European Union (EU) has resumed after clock-stop. The conclusion of this centralized procedure is expected for Q4/2018.
-
AOP Orphan Pharmaceuticals AG And PharmaEssentiaAnnounce Latest Clinical Results For Ropeginterferon Alfa-2b In Polycythemia Vera From 3 Abstracts Presented At The 22nd Congress Of The European Hematology Association In Madrid
6/26/2017
-
AOP Orphan Pharmaceuticals AG And PharmaEssentia Announce Pivotal Phase III Results For Ropeginterferon Alfa-2b In Polycythemia Vera At The American Society of Hematology Annual Meeting 2016
12/5/2016
-
AOP Orphan Pharmaceuticals AG Announces European "Approvable" Opinion Of Its Ultra-Short Acting Beta Blocker Rapibloc (Landiolol)
7/11/2016
-
AOP Orphan Pharmaceuticals AG Announces Launch Of Access Program For The World’s First Drug Against Lipodystrophy In HIV Patients, EGRIFTA, In Europe
8/11/2015
-
AOP Orphan Pharmaceuticals AG Strengthens Core CNS Specialty Business With High Promise In Movement Disorder Treatments
6/19/2015
-
AOP Orphan Pharmaceuticals AG Release: Innovative Antipsychotic ADASUVE To Benefit Even More Patients
5/28/2015
-
Cardiome Pharma Corp. And AOP Orphan Pharmaceuticals AG Enter ESMOCARD Commercialization Agreement
5/12/2015
-
AOP Orphan Pharmaceuticals AG Launches Lojuxta (Lomitapide) For Treatment Of Homozygous Familial Hypercholesterolaemia To The Austrian Market
4/30/2015
-
AOP Orphan Pharmaceuticals AG And Rigi Healthcare Start Rigi Orphan Inc., USA
4/8/2015
-
Confluence Pharmaceuticals Signs Co-Development And Marketing Agreement With AOP Orphan Pharmaceuticals AG For Fragile X Syndrome Drug
3/23/2015
-
AOP Orphan Pharmaceuticals AG Announces Progress Of Pivotal Phase 3 Trial PROUD-PV Applying Ropeginterferon ALFA 2B, A Novel, Long-Acting, Mono-Pegylated Interferon For Treatment Of Polycythemia Vera
3/5/2015
-
Partnership Between AOP Orphan Pharmaceuticals AG and Ferrer Internacional: Joint Marketing of Adasuve® in CEE
10/29/2013